TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating the combination of ublituximab, the Company's investigational anti-CD20 monoclonal antibody and UKONIQ® (umbralisib), the Company's inhibitor of PI3K-delta and CKI-epsilon, (U2), as well as U2-based triple combination therapies, including U2 plus TG's investigational BTK inhibitor TG-1701. Data presentations occurred this past weekend during the 63rd American Society of Hematology (ASH) annual meeting and exposition. Presentation highlights are included below.

TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.

TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting

The stock price of TG Therapeutics, a commercial stage biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases, has seen a large 50% fall over the last month, while it is up 15% over the last five trading days.

Is A Rise Imminent For TG Therapeutics Stock After A Large 50% Fall In A Month?

The FDA asked for an adcomm over OS concerns and brought down TGTX stock. OS was not a part of the agreed upon study protocol, and data was not mature, and study was not powered for OS.

TG Therapeutics Debacle: I Am Doubling Down

NEW YORK--(BUSINESS WIRE)-- #Securities--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) on behalf of TG Therapeutics stockholders. Our investigation concerns whether TG Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 30, 2021, TG Therapeutics iss

TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TG Therapeutics, Inc. on Behalf of TG Therapeutics Stockholders and Encourages Investors to Contact the Firm

Atlanta, Georgia--(Newsfile Corp. - December 1, 2021) - Holzer & Holzer, LLC is investigating whether TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX) complied with federal securities laws. On November 30, 2021, TG Therapeutics provided a regulatory update, advising that "the U.S. Food and Drug Administration (FDA) has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee (ODAC) in connection with its review of the pending...

SHAREHOLDER ALERT: Investigation of TG Therapeutics, Inc. Announced by Holzer & Holzer, LLC

TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo). U2 Combo application seeks approval for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate

Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.

Why TG Therapeutics Is Plunging More Than 40% Today

TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Tuesday after the company reported the U.S. Food and Drug Administration plans to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the pending Biologics License Application/supplemental New Drug Application for the combination of ublituximab and UKONIQ. The combination of ublituximab and UKONIQ is used for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Why TG Therapeutics Stock Is Falling Today

TG Therapeutics Inc (NASDAQ:TGTX) stock is plummeting today, down 45.4% to trade at $12.75 at last check.

TG Therapeutics Stock Plummets After FDA Update

Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET

TG Therapeutics Provides Regulatory Update

A new call from a well-known Wall Street firms casts a fresh shadow of doubt on the drugmaker's actual revenue prospects.

Why TG Therapeutics Is Crashing Today

Fireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021 Fireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021

TG Therapeutics to Participate in the Jefferies London Healthcare Conference

Fireside chat scheduled for 12:00 PM ET on Thursday November 11, 2021 Fireside chat scheduled for 12:00 PM ET on Thursday November 11, 2021

TG Therapeutics to Participate in the B. Riley Securities Fall 2021 Growth Biotech Best Ideas Virtual Series

TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q3 2021 Results - Earnings Call Transcript

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -16.07% and -37.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the release of six abstracts that will be presented at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia. Abstracts are now publicly available online via the ASH meeting website at www.hematology.org.

TG Therapeutics Highlights Data Selected for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET

TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Conference call to be held Thursday, November 4, 2021 at 8:30 AM ET Conference call to be held Thursday, November 4, 2021 at 8:30 AM ET

TG Therapeutics to Host Conference Call on Third Quarter 2021 Financial Results and Business Update

New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score

TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company's investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis (RMS). The submission was based on the results of the ULTIMATE I & II trials, two identical Phase 3, randomized, global, multi-center, double-blinded, active-controlled trials evaluating ublituximab compared to teriflunomide in patients with RMS. The ULTIMATE I & II trials were conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

The ULTIMATE I & II Phase 3 trials both have met their primary endpoint with ublituximab treatment demonstrating a statistically significant reduction in annualized relapse rate (ARR) over a 96-week period (p

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021 Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021

TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET

News for TG Therapeutics Stock (TGTX)